Literature DB >> 16026159

Anion binding and controlled aggregation of human interleukin-1 receptor antagonist.

Andrei A Raibekas1, Edward J Bures, Christine C Siska, Tadahiko Kohno, Ramil F Latypov, Bruce A Kerwin.   

Abstract

Highly concentrated human recombinant interleukin-1 receptor antagonist (IL-1ra) aggregates at elevated temperature without perturbation in its secondary structure. The protein aggregation can be suppressed depending on the buffer ionic strength and the type of anion present in the sample solution. Phosphate is an approximately 4-fold weaker suppressant than either citrate or pyrophosphate on the basis of the measured protein aggregation rates. This is in agreement with the strength of protein-anion interactions at the IL-1ra single anion-binding site as judged by the estimated dissociation constant values of 2.9 mM, 3.8 mM, and 13.7 mM for pyrophosphate, citrate, and phosphate, respectively. The strength of binding also correlates with the anion size and with the number of ionized groups available per molecule at a given pH. Affinity probing of IL-1ra with methyl acetyl phosphate (MAP) in combination with proteolytic digestion and mass spectral analysis show that an anion-binding site location on the IL-1ra surface is contributed by lysine-93 and lysine-96 of the loop 84-98 as well as by lysine-6 of the unstructured N-terminal region 1-7. The replacement of lysine-93 with alanine by site-directed mutagenesis results in dramatically suppressed IL-1ra aggregation. Furthermore, when the unstructured N-terminal region of IL-1ra is removed by limited proteolysis, a 2-fold increase in the time course of the aggregation lag phase is observed for the truncated protein. An anion-controlled mechanism of IL-1ra aggregation is proposed by which the anion competition for the protein cationic site prevents formation of intermolecular cation-pi interactions and, thus, interferes with the protein asymmetric self-association pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16026159     DOI: 10.1021/bi050388g

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

Review 1.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

2.  Design of a superior cytokine antagonist for topical ophthalmic use.

Authors:  Jinzhao Hou; Sharon A Townson; Joseph T Kovalchin; Allyson Masci; Olga Kiner; Yanqun Shu; Bracken M King; Emily Schirmer; Kathryn Golden; Christoph Thomas; K Christopher Garcia; Gregory Zarbis-Papastoitsis; Eric S Furfine; Thomas M Barnes
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

3.  Protein-protein interactions controlling interfacial aggregation of rhIL-1ra are not described by simple colloid models.

Authors:  Lea L Sorret; Madison A DeWinter; Daniel K Schwartz; Theodore W Randolph
Journal:  Protein Sci       Date:  2018-03-03       Impact factor: 6.725

4.  Orthogonal high-throughput thermal scanning method for rank ordering protein formulations.

Authors:  Vishal C Nashine; Andrew M Kroetsch; Erinc Sahin; Rong Zhou; Monica L Adams
Journal:  AAPS PharmSciTech       Date:  2013-09-04       Impact factor: 3.246

Review 5.  Mass Spectrometry-Based Protein Footprinting for Higher-Order Structure Analysis: Fundamentals and Applications.

Authors:  Xiaoran Roger Liu; Mengru Mira Zhang; Michael L Gross
Journal:  Chem Rev       Date:  2020-04-22       Impact factor: 60.622

6.  Effect of benzyl alcohol on recombinant human interleukin-1 receptor antagonist structure and hydrogen-deuterium exchange.

Authors:  John R Alford; Andrew C Fowler; Deborah S Wuttke; Bruce A Kerwin; Ramil F Latypov; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2011-05-05       Impact factor: 3.534

7.  Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.

Authors:  Francisco Amparo; Mohammad H Dastjerdi; Andre Okanobo; Giulio Ferrari; Leila Smaga; Pedram Hamrah; Ula Jurkunas; Debra A Schaumberg; Reza Dana
Journal:  JAMA Ophthalmol       Date:  2013-06       Impact factor: 7.389

8.  High concentration formulations of recombinant human interleukin-1 receptor antagonist: I. Physical characterization.

Authors:  John R Alford; Stanley C Kwok; Jennifer N Roberts; Deborah S Wuttke; Brent S Kendrick; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2008-08       Impact factor: 3.534

9.  Multistep aggregation pathway of human interleukin-1 receptor antagonist: kinetic, structural, and morphological characterization.

Authors:  Sampathkumar Krishnan; Andrei A Raibekas
Journal:  Biophys J       Date:  2009-01       Impact factor: 4.033

10.  Structural and thermodynamic effects of ANS binding to human interleukin-1 receptor antagonist.

Authors:  Ramil F Latypov; Dingjiang Liu; Kannan Gunasekaran; Timothy S Harvey; Vladimir I Razinkov; Andrei A Raibekas
Journal:  Protein Sci       Date:  2008-02-27       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.